Danaher (DHR) Set to Announce Quarterly Earnings on Tuesday

Danaher (NYSE:DHR) will be issuing its quarterly earnings data before the market opens on Tuesday, October 22nd. Analysts expect the company to announce earnings of $1.55 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.05 EPS. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Stock Performance

NYSE DHR opened at $271.56 on Tuesday. The firm has a market cap of $201.14 billion, a price-to-earnings ratio of 46.03, a PEG ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a 50 day moving average of $270.36 and a 200-day moving average of $259.43.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last ninety days. 11.10% of the stock is owned by insiders.

Analysts Set New Price Targets

DHR has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Robert W. Baird upped their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.